Dianthus Therapeutics (DNTH) Stock May Look Stretched As Pipeline Progress Draws Focus
Wall Street Analysts See a 61.23% Upside in Dianthus Therapeutics, Inc. (DNTH): Can the Stock Really Move This High?
Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Beats Revenue Estimates
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 2026 Financial Results
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dianthus Therapeutics to Participate in Five Investor Conferences During November
Roth Capital Initiates Coverage On Dianthus Therapeutics with Buy Rating, Announces Price Target of $113
Dianthus Therapeutics (DNTH) Stock May Be Above Fair Value Following Its 5x Run
HC Wainwright & Co. Reiterates Buy on Dianthus Therapeutics, Maintains $158 Price Target
Dianthus Therapeutics Named to Fortune’s 2026 Best Workplaces in BioPharma List Amid Company Expansion
Dianthus Therapeutics Recognized Among Fortune’s 2026 Best Workplaces In BioPharma
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting
Can Dianthus Therapeutics (DNTH) Stay Undervalued Following Its $500 Million Stock Offering?
Dianthus Therapeutics (DNTH) Stock Looks Expensive After A 7x Run
JP Morgan Initiates Coverage On Dianthus Therapeutics with Overweight Rating, Announces Price Target of $135
Dianthus Therapeutics, Inc. (DNTH) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Dianthus (DNTH) Piles Up Clinical Wins While Its Losses Widen
Citigroup Initiates Coverage On Dianthus Therapeutics with Buy Rating, Announces Price Target of $156
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.